Compare CVM & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVM | TXMD |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 25.9M |
| IPO Year | 1996 | 2012 |
| Metric | CVM | TXMD |
|---|---|---|
| Price | $3.50 | $2.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 38.3K | 19.6K |
| Earning Date | 02-18-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.61 |
| EPS | N/A | ★ N/A |
| Revenue | $264,033.00 | ★ $1,761,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.64 |
| Revenue Growth | ★ 65.45 | 35.25 |
| 52 Week Low | $0.18 | $0.83 |
| 52 Week High | $13.48 | $2.95 |
| Indicator | CVM | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 48.54 |
| Support Level | $3.40 | $2.10 |
| Resistance Level | $6.75 | $2.35 |
| Average True Range (ATR) | 0.30 | 0.11 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 20.65 | 57.14 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.